Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCH 900271 in Primary Hypercholesterolemia or Mixed Hyperlipidemia
NCT00941603Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2009
- Primary completion
- Feb 2010
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of sch-900271 in hypercholesterolemia and mixed hyperlipidemia (6 arms), sponsored by Merck & Co. Primary endpoint: Change From Baseline in Direct LDL-C at 8 weeks. Started Jun 2009; status: completed.
02
Drugs
sch-900271
03
Conditions
hypercholesterolemiamixed hyperlipidemia
Beyond the preview
Go deeper on NCT00941603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00941603.